Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $1.9 million.

  • Immunome's Change in Account Payables rose 18875.71% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 66335.7%. This contributed to the annual value of $9.5 million for FY2024, which is 166677.63% up from last year.
  • Immunome's Change in Account Payables amounted to $1.9 million in Q3 2025, which was up 18875.71% from -$4.9 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Change in Account Payables peaked at $9.3 million during Q4 2024, and registered a low of -$4.9 million during Q2 2025.
  • Its 3-year average for Change in Account Payables is $184636.4, with a median of -$32000.0 in 2024.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 146524.3% in 2024, then tumbled by 1536250.0% in 2025.
  • Quarter analysis of 3 years shows Immunome's Change in Account Payables stood at -$679000.0 in 2023, then surged by 1465.24% to $9.3 million in 2024, then plummeted by 79.82% to $1.9 million in 2025.
  • Its Change in Account Payables was $1.9 million in Q3 2025, compared to -$4.9 million in Q2 2025 and -$3.8 million in Q1 2025.